Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Major Shareholder Sells 860,123 Shares of Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) major shareholder Orbimed Advisors Llc sold 860,123 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $45.36, for a total transaction of $39,015,179.28. Following the transaction, the insider owned 219,405 shares of the company’s stock, valued at approximately $9,952,210.80. The trade was a 79.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, June 15th, Orbimed Advisors Llc sold 281,408 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $45.02, for a total value of $12,668,988.16.

Bitwise MARA Option Income Strategy ETF Price Performance

Shares of Bitwise MARA Option Income Strategy ETF stock traded down $0.56 on Wednesday, hitting $17.03. 604 shares of the company’s stock traded hands, compared to its average volume of 5,314. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $54.94. The company has a fifty day moving average of $16.69 and a two-hundred day moving average of $15.74. The company has a market capitalization of $3.24 million, a price-to-earnings ratio of 340.60 and a beta of 2.88.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.